Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(2)
Key new findings by the Institut Pasteur concerning the gene target GJB2, enables Sensorion to potentially address important hearing loss segments in adults and children
GJB2 mutations are the most prevalent cause of congenital deafness; the gene target potentially opens up a pipeline of indications
Three initial indications to be targeted: congenital deafness, a progressive form of hearing loss in childhood and early onset of severe presbycusis in adults
Webcast planned for Tuesday, February 16 at 2:00pm CET
Regulatory News:
Sensorion (Paris:ALSEN)(FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the addition of a new gene therapy target,